Key real-world results for Sputnik V and Sputnik Light vaccines

Main
About Sputnik V
Official data

Official data on Sputnik V around the world confirms its highest safety and efficacy profile

Real data provided by cooperation of RDIF and various Health Ministries

Russia

UAE

Bahrain

Argentina

Hungary

Mexico

Russia

Sputnik V is one of the most effective COVID-19 vaccines in the world

Sputnik V’s real-world efficacy,
according to analysed data from 3.8 mn vaccinated Russians

serious adverse events or vaccination-related deaths
hospitalisation, cerebral venous thrombosis (CVT) cases or cases of myocarditis after vaccination

Source: Gamaleya Research Centre for Epidemiology and Microbiology. April 19, 2021

Sputnik V vaccine is effective against new variants of coronavirus

Vaccination with Sputnik V has produced protective
neutralizing antibody titers against:

Alpha B.1.1.7 (first identified in UK)
Beta B.1.351 (South Africa)
Gamma P.1 (Brazil)
Delta B.1.617.2 and B.1.617.3 (India)

Source: Gamaleya Research Centre for Epidemiology and Microbiology (Published in Vaccines leading international journal). July 12, 2021

Sputnik V demonstrates high efficacy against the Delta variant

Sputnik V is 83.1% effective against the Delta variant with
6x reduction in infection risk

Sputnik V is 94.4% effective against hospitalisations with
18x reduction in hospitalisation risk

Source: Ministry of Health of Russian Federation

UAE

Sputnik V demonstrated high safety and efficacy during the vaccination campaign in UAE Based on analysis of over 81,000 vaccinated individuals

97.8%

efficacy after the 2^nd shot

100%

efficacy against severe COVID-19 cases

serious adverse events
or vaccination-related deaths
hospitalisation, cerebral venous thrombosis (CVT) cases or case of myocarditis after vaccination

Source: UAE Ministry of Health. June 8, 2021

Bahrain

Sputnik V showed high efficacy and safety in BahrainBased on analysis of over 5,000 vaccinated individuals

94.3%

efficacy*

98.6%

of all COVID-19 cases were mild*

serious adverse events, cerebral venous thrombosis cases or vaccine-related deaths

* 14 days after the 2^nd shot
Source: Bahrain Ministry of Health. June 10, 2021

Argentina

Sputnik V induces highest immune response according to official data from Argentina

vaccinated developed antibodies against COVID-19
after the 2^nd shot

Best safety rates in Buenos Aires (based on analysis of over 5 mn doses administered):

vaccine-related deaths

The lowest rate of serious adverse events (hospitalisations)

Source: Ministry of Health of the Province of Buenos Aires (Argentina). April 13, 2021
Ministry of Health of the Province of Buenos Aires (Argentina). June 24, 2021

Confirmed neutralisation effectiveness of Sputnik V against the Manaus (Brazilian) variant in Argentina

Source: Argentina’s Institute of Virology of the National University of Cordoba and the Government of Cordoba.
May 2021

the efficacy of Sputnik Light (1st component of Sputnik V) among the elderly in Argentina
according to the data from over 186,000 people

Source: Ministry of Health of the Province of Buenos Aires (Argentina). June 2021

Sputnik Light (1st component of Sputnik V) induces high immune response according to official data from Argentina

of vaccinated developed antibodies against COVID-19

Source: Ministry of Health of the Province of Buenos Aires (Argentina). April 13, 2021

Hungary

Sputnik V demonstrates best efficacy rate in Hungary

Infection rate per 100,000
vaccinated

cerebral venous thrombosis (CVT) cases or vaccination-related deaths

Source: Government of Hungary. April 25, 2021

Mexico

Sputnik V demonstrates the highest safety with the lowest ratio of serious adverse events in MexicoBased on analysis of over 36 mn administered doses No link between vaccination and serious adverse events was found

Number of serious
adverse events per 100,000 shots

Source: Ministry of Health and Government of Mexico